LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Lyell Immunopharma Inc

Chiusa

0.42 5

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.4

Massimo

0.42

Metriche Chiave

By Trading Economics

Entrata

140M

-52M

Vendite

-4K

7K

EPS

-0.18

Margine di Profitto

-745,642.857

Dipendenti

300

EBITDA

58M

-119K

Raccomandazioni

By TipRanks

Raccomandazioni

Vendi

Previsioni per 12 mesi

+150% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1M

123M

Apertura precedente

-4.58

Chiusura precedente

0.42

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Lyell Immunopharma Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 mag 2025, 10:30 UTC

Notizie principali

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31 mag 2025, 06:30 UTC

Utili

5 Things We've Learned From Retail Earnings -- Barrons.com

31 mag 2025, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

30 mag 2025, 23:51 UTC

Acquisizioni, Fusioni, Takeovers

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 mag 2025, 21:30 UTC

Notizie principali

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 mag 2025, 21:15 UTC

Notizie principali

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 mag 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

30 mag 2025, 20:44 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 mag 2025, 20:24 UTC

Notizie principali

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 mag 2025, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

30 mag 2025, 19:44 UTC

Discorsi di Mercato

Gold Breaks 4-Month Winning Streak -- Market Talk

30 mag 2025, 19:38 UTC

Discorsi di Mercato

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 mag 2025, 19:29 UTC

Utili
Acquisizioni, Fusioni, Takeovers

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 mag 2025, 19:14 UTC

Discorsi di Mercato

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 mag 2025, 19:05 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 mag 2025, 18:51 UTC

Discorsi di Mercato

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 mag 2025, 18:37 UTC

Discorsi di Mercato
Utili

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 mag 2025, 18:04 UTC

Notizie principali

S&P 500 Falls After More Trump-China Friction -- WSJ

30 mag 2025, 17:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 mag 2025, 17:47 UTC

Discorsi di Mercato

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 mag 2025, 17:40 UTC

Acquisizioni, Fusioni, Takeovers

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 mag 2025, 17:38 UTC

Discorsi di Mercato

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 mag 2025, 17:31 UTC

Discorsi di Mercato

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 mag 2025, 17:14 UTC

Notizie principali

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 mag 2025, 16:31 UTC

Utili

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 mag 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

30 mag 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

30 mag 2025, 16:16 UTC

Notizie principali

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 mag 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

30 mag 2025, 16:14 UTC

Notizie principali

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Confronto tra pari

Modifica del prezzo

Lyell Immunopharma Inc Previsione

Obiettivo di Prezzo

By TipRanks

150% in crescita

Previsioni per 12 mesi

Media 1 USD  150%

Alto 1 USD

Basso 1 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lyell Immunopharma Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Vendi

3 ratings

0

Acquista

2

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

0.4217 / 0.4691Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.